Rectal Cancer
Rectal cancer requires precise staging with pelvic MRI to determine resectability, mesorectal fascia involvement, and the role of neoadjuvant chemoradiation or total neoadjuvant therapy before surgery. MSI-H tumors have shown exceptional responses to immunotherapy, sometimes avoiding surgery entirely. CancerFax helps patients access total neoadjuvant therapy programs, organ-preservation strategies, and specialist colorectal surgery review.
- Pelvic MRI staging, CRM & MSI-H assessment
- Total neoadjuvant therapy & organ-preservation access
- Colorectal surgery specialist & international second opinion
- Annual Incidence (US)
- ~46,950 cases
- Median Age at Diagnosis
- ~70 years
- 5-Year Survival (Overall)
- ~67%
- 5-Year Survival (Stage I)
- 85-90%
- 5-Year Survival (Stage IV)
- 10-15%
What is Rectal Cancer
Types and Subtypes
Rectal cancers are classified by histologic type, anatomic location within the rectum, and molecular features. Adenocarcinoma is by far the most common type. Anatomic location (upper, middle, lower rectum) and distance from anal sphincter significantly impact surgical approach and sphincter-sparing potential. Molecular features including MSI status and KRAS/BRAF mutations impact treatment response and prognosis.
Symptoms and Signs
Rectal cancer symptoms vary depending on tumor location, size, and stage. Early-stage disease may be asymptomatic or present with subtle symptoms. Advanced disease typically presents with more obvious symptoms. Any persistent rectal symptom lasting more than two weeks should be evaluated by a healthcare provider.
Causes and Risk Factors
Rectal cancer arises from clonal expansion of epithelial cells with acquired genetic and epigenetic abnormalities. Multiple risk factors have been identified, with age being the most important. Hereditary conditions and inflammatory bowel disease significantly increase risk.
Diagnosis and Investigations
Diagnosis of rectal cancer requires clinical suspicion, tissue diagnosis, and staging investigations. Colonoscopy with biopsy is essential for confirming diagnosis. Imaging and molecular testing are critical for staging and prognostic assessment.
Disease Staging and Risk Stratification
TNM staging is standard for rectal cancer. Tumor (T) stage based on depth of invasion; Node (N) stage based on lymph node involvement; Metastasis (M) stage based on distant spread. Circumferential resection margin (CRM) status is critical prognostic factor. Overall stage guides treatment decisions and prognosis.
Standard Treatment Options
Rectal cancer treatment is multimodal, depending on the TNM staging, site of the tumor, characteristics of the tumor, the age of the patient, co-morbidity, and performance status of the patient. Early disease stages (Stages 0-1) can be managed by either endoscopic resection or surgical intervention alone. Advanced disease stages (Stages 2-3) will need neoadjuvant chemoradiotherapy along with surgery and chemotherapy.
Advanced & Emerging Therapies
Advances in rectal cancer treatment include improved surgical techniques (total mesorectal excision, sphincter-sparing approaches), intensity-modulated radiation therapy (IMRT), targeted therapies, and immunotherapy. Emerging approaches focus on improving outcomes while reducing treatment toxicity and preserving sphincter function.
Surgical Therapy
Total Mesorectal Excision (TME)
Standard surgical technique for rectal cancer. Removes rectum with surrounding mesorectal fat and lymph nodes. Reduces local recurrence risk. Preserves sphincter function when possible.
Surgical Therapy
Sphincter-Sparing Surgery
Low anterior resection (LAR) with primary anastomosis for mid/upper rectal tumors. Preserves continence and avoids colostomy. Requires adequate distance from anal sphincter.
Radiation Therapy
Intensity-Modulated Radiation Therapy (IMRT)
Advanced radiation technique for neoadjuvant chemoradiation. Delivers high doses to tumor while minimizing dose to normal tissues. Reduces toxicity compared to conventional radiation.
Chemotherapy
Neoadjuvant Chemoradiation
Preoperative chemotherapy (5-FU based) combined with radiation. Standard for Stage II-III rectal cancer. Improves local control and allows sphincter-sparing surgery in selected cases.
Chemotherapy
Adjuvant Chemotherapy (FOLFOX/CAPOX)
Postoperative chemotherapy for Stage III and high-risk Stage II disease. 5-FU based regimens (FOLFOX or CAPOX). Improves overall survival.
Targeted Therapy
Bevacizumab (Anti-VEGF)
Monoclonal antibody targeting vascular endothelial growth factor (VEGF). Used for metastatic disease in combination with chemotherapy. Improves survival.
Targeted Therapy
EGFR Inhibitors (Cetuximab, Panitumumab)
Monoclonal antibodies targeting epidermal growth factor receptor (EGFR). Used for metastatic disease in KRAS wild-type tumors. Improves survival.
Immunotherapy
Checkpoint Inhibitors (Pembrolizumab, Nivolumab)
PD-1 inhibitors approved for metastatic MSI-high rectal cancer. Improves outcomes compared to chemotherapy for MSI-high tumors.
Biomarkers & Molecular Features
Molecular features including MSI status, KRAS/BRAF mutations, and TP53 mutations significantly impact treatment decisions and prognosis. MSI-high tumors have better prognosis and respond to immunotherapy. KRAS status predicts response to EGFR inhibitors. Circumferential resection margin (CRM) status is critical prognostic factor.
When to Seek a Second Opinion
Expert review is valuable in rectal cancer given the complexity of staging, treatment planning, and multimodal therapy coordination. Second opinion recommended at multiple points in the disease course.
Clinical Trials & Research
Prognosis & Outcome Factors
Prognosis in rectal cancer depends primarily on TNM stage and circumferential resection margin (CRM) status. Early-stage disease (Stage 0-I) has excellent prognosis with 5-year survival 85-95%. Locally advanced disease (Stage II-III) has intermediate prognosis with 5-year survival 50-80%. Metastatic disease has poor prognosis with 5-year survival 10-15%. Molecular features including MSI status and KRAS mutations also impact prognosis and treatment response.
Supportive Care & Living With Rectal Cancer
Supportive care is an essential component of rectal cancer management, addressing both the acute effects of disease and treatment-related complications. Patients need comprehensive support for managing treatment side effects, maintaining continence, and psychosocial support.
How CancerFax Helps You Explore Treatment Options
CancerFax assists patients with rectal cancer by coordinating expert review of colonoscopy biopsy pathology, imaging studies (CT, MRI, PET-CT), TNM staging, CEA levels, and molecular testing (MSI status, KRAS/BRAF mutations) to confirm accurate rectal cancer diagnosis, stage, and prognostic factors. We connect patients with colorectal surgical oncologists, radiation oncologists, and medical oncologists experienced in rectal cancer management. We facilitate access to neoadjuvant chemoradiation, total mesorectal excision (TME), adjuvant chemotherapy, targeted therapy (bevacizumab, cetuximab), immunotherapy, and clinical trial opportunities at major colorectal cancer centers globally, including specialized institutions in China.
Get a free case reviewFrequently Asked Questions
Rectal cancer is a malignant neoplasm of the rectum, the portion of the large intestine extending 10-15 cm from the anal verge. Adenocarcinoma accounts for approximately 95% of rectal cancers. Rectal cancer affects approximately 46,950 people annually in the United States and 154,000 globally.
Major risk factors include age (>50 years), family history of colorectal cancer, personal history of polyps or cancer, inflammatory bowel disease, smoking, excessive alcohol use, obesity, and sedentary lifestyle. Hereditary conditions (FAP, Lynch syndrome) significantly increase risk.
Symptoms include rectal bleeding or blood in stool, change in bowel habits (diarrhea, constipation), pencil-thin stools, tenesmus (feeling of incomplete evacuation), abdominal pain, weight loss, and weakness. Any persistent rectal symptom lasting more than two weeks should be evaluated.
Diagnosis requires colonoscopy with biopsy confirming malignancy. Imaging studies (CT, MRI, PET-CT) assess tumor extent and lymph node involvement. Molecular testing (MSI status, KRAS/BRAF mutations) determines treatment response. TNM staging combines tumor size, lymph node involvement, and distant metastases.
TNM staging combines Tumor depth (T), Node involvement (N), and Metastasis (M). Stage 0-I disease (early-stage) has excellent prognosis (85-95% 5-year survival). Stage II-III (locally advanced) has intermediate prognosis (50-80% 5-year survival). Stage IV (metastatic) has poor prognosis (10-15% 5-year survival).
Neoadjuvant chemoradiation is preoperative chemotherapy combined with radiation therapy. Standard treatment for Stage II-III rectal cancer. Improves local control, reduces recurrence risk, and allows sphincter-sparing surgery in selected cases. Followed by surgery and adjuvant chemotherapy.
TME is standard surgical technique for rectal cancer. Removes rectum with surrounding mesorectal fat and lymph nodes. Reduces local recurrence risk compared to conventional surgery. Preserves sphincter function when possible (low anterior resection) or requires colostomy for very low tumors (abdominoperineal resection).
CRM is the distance between the tumor and the outer edge of the surgical specimen. CRM >=1 mm associated with better local control. CRM <1 mm associated with higher recurrence risk. Critical prognostic factor independent of TNM stage. Assessed on MRI and pathology.
Yes. CancerFax helps patients with rectal cancer by coordinating expert review of colonoscopy biopsy pathology, imaging studies, TNM staging, and molecular testing. We connect patients with colorectal surgical oncologists and radiation oncologists experienced in rectal cancer management. We facilitate access to neoadjuvant therapy, surgery, adjuvant chemotherapy, targeted therapy, immunotherapy, and clinical trials.